Anemia Work-Up and Management in This Patient
This patient requires immediate evaluation for gastrointestinal bleeding given the combination of anemia (Hgb 10.9, Hct 31.6, RBC 3.4) and elevated BUN (40) with only mildly elevated creatinine (1.15), creating a disproportionate BUN:creatinine ratio suggestive of upper GI blood loss. 1
Immediate Diagnostic Steps
The anemia work-up should include:
- Complete blood count with indices (already done - shows normocytic anemia based on the values)
- Reticulocyte count to assess bone marrow response
- Iron studies: serum ferritin and transferrin saturation to identify absolute or functional iron deficiency 1
- Vitamin B12 level (already ordered - appropriate)
- Folate level
- Stool guaiac or fecal immunochemical test for occult blood
The elevated BUN:creatinine ratio (>20:1) is a critical finding. With BUN 40 and creatinine 1.15, this ratio is approximately 35:1, which strongly suggests upper GI bleeding as a source of the anemia rather than CKD-related anemia alone 1. Blood in the GI tract is digested and absorbed, raising BUN disproportionately to creatinine.
Medication-Related Considerations
Auvelity (Dextromethorphan-Bupropion)
Neither component directly causes anemia, but bupropion can cause nausea and GI upset that might contribute to occult bleeding if NSAIDs or other ulcerogenic agents are used concurrently 2. The current dose (45-105 mg daily) is the standard therapeutic dose 3, 4.
Caplyta (Lumateperone)
The dose listed (10.5 mg) appears to be a transcription error - Caplyta is dosed at 42 mg once daily for depression 5, 6. This should be clarified immediately. Lumateperone does not cause anemia but can affect metabolic parameters including glucose 5.
Metabolic Issues
The elevated glucose requires fasting glucose measurement and HbA1c testing. Both Auvelity and Caplyta can affect glucose metabolism, though Caplyta carries more significant metabolic risk 5. The Caplyta label specifically warns about hyperglycemia and recommends monitoring fasting plasma glucose before initiation and periodically during treatment 5.
Renal Function Assessment
The mildly elevated creatinine (1.15) with high BUN suggests either:
- Upper GI bleeding (most likely given the ratio)
- Early renal impairment
- Dehydration
Calculate the estimated GFR to determine if dose adjustments are needed for either medication. Neither Auvelity nor Caplyta requires dose adjustment for mild renal impairment, but this should be monitored 2, 5.
Management Algorithm
- Urgent: Evaluate for GI bleeding with stool testing and consider gastroenterology referral if positive
- Immediate: Complete iron studies, reticulocyte count, folate level
- Verify medication dosing: Confirm the Caplyta dose (should be 42 mg, not 10.5 mg)
- Metabolic work-up: Fasting glucose and HbA1c for diabetes screening
- Renal assessment: Calculate eGFR and monitor trend
- If iron deficiency confirmed: Initiate iron supplementation and investigate source of blood loss 1
- Monitor: Repeat CBC in 4-6 weeks after initiating treatment
Critical Pitfalls to Avoid
- Do not attribute anemia solely to psychiatric medications without ruling out GI bleeding, especially with this BUN:creatinine ratio
- Do not overlook the medication dosing discrepancy - 10.5 mg of Caplyta is not a standard dose
- Do not delay GI evaluation if stool is guaiac positive - this patient may need endoscopy
- Do not ignore the glucose elevation - both medications can worsen glycemic control, and baseline diabetes screening is essential before continuing therapy 5
The normal TSH (1.5) and liver enzymes (ALT 30, AST 24) are reassuring and make thyroid disease and primary liver pathology unlikely contributors to the anemia 1.